Cefpirome: Difference between revisions
No edit summary |
m Protected "Cefpirome": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
(One intermediate revision by one other user not shown) | |||
Line 61: | Line 61: | ||
== Spectrum of bacterial susceptibility and resistance == | == Spectrum of bacterial susceptibility and resistance == | ||
''[[Bacteroides fragilis]]'', [[enterococci]], ''[[Pseudomonas]]'' spp. and [[staphylococci]] are resistant to cefpirome sulfate, and some ''[[Haemophilus]]'' spp. and [[pneumococci]] have developed resistance to it to varying degrees. | ''[[Bacteroides fragilis]]'', [[enterococci]], ''[[Pseudomonas]]'' spp. and [[staphylococci]] are resistant to cefpirome sulfate, and some ''[[Haemophilus]]'' spp. and [[pneumococci]] have developed resistance to it to varying degrees. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Latest revision as of 18:49, 18 August 2015
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C22H22N6O5S2 |
Molar mass | 514.58 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Cefpirome |
Articles |
---|
Most recent articles on Cefpirome |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Cefpirome at Clinical Trials.gov Clinical Trials on Cefpirome at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Cefpirome
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Cefpirome Discussion groups on Cefpirome Directions to Hospitals Treating Cefpirome Risk calculators and risk factors for Cefpirome
|
Healthcare Provider Resources |
Causes & Risk Factors for Cefpirome |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cefpirome is a fourth-generation cephalosporin. Trade names include Cefrom, Keiten, Broact, and Cefir. Cefpirome is considered highly active against Gram-negative bacteria, including Pseudomonas aeruginosa, and Gram-positive bacteria.
Spectrum of bacterial susceptibility and resistance
Bacteroides fragilis, enterococci, Pseudomonas spp. and staphylococci are resistant to cefpirome sulfate, and some Haemophilus spp. and pneumococci have developed resistance to it to varying degrees.
References
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Cephalosporin antibiotics
- Thiazoles
- Drug